This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Vidarikand (Pueraria tuberosa) is a perennial herb used in traditional Asian medicine, particularly Ayurveda, for its restorative and therapeutic properties [PMID:24980468, PMID:33708108].
Background
Pueraria tuberosa (Willd.) DC, also known as Indian Kudzu, is a perennial herb of the Fabaceae family distributed throughout India and Southeast Asia [PMID:24980468, PMID:33708108].
Traditional uses
In Ayurveda, the tuber is used as a restorative tonic, antiaging agent, spermatogenic, and immune booster [PMID:24980468]. It is traditionally recommended for cardiovascular diseases, hepatosplenomegaly, fertility disorders, menopausal syndrome, sexual debility, and spermatorrhoea [PMID:24980468].
Active compounds
The tuber contains isoflavonoids including puerarin, genistein, daidzein, and tuberosin [PMID:24980468, PMID:33708108]. Other identified constituents include mangiferin, isoorientin, robinin, genistin, daidzin, and various polyphenols, alkaloids, and phytosterols [PMID:28218280, PMID:28243356, PMID:34424815, PMID:36986988].
Mechanism of action
Puerarin modulates oxidative stress, apoptosis, cell cycle, and pathways including NF-kB, PI3K/AKT/mTOR, and AMPK to exert anticancer effects [PMID:32021425]. Mangiferin reduces inflammation by inactivating the NLRP3 inflammasome and inhibiting NF-kB translocation [PMID:28218280]. Isoorientin acts as a selective COX-2 inhibitor [PMID:28243356].
Clinical evidence
Evidence BStage 1 Hypertension
Administration of 3g of P. tuberosa over 12 weeks significantly reduced systolic (25 mmHg), diastolic (11 mmHg), and mean (16 mmHg) blood pressure, while enhancing plasma fibrinolytic activity and total antioxidant status [PMID:24171260]
Evidence DSexual Behavior and Androgenesis
Ethanolic extract in male rats caused a dose-dependent increase in sexual behaviors, increased testis weight, and elevated levels of FSH, LH, and testosterone [PMID:24489512]
Evidence DDiabetes-induced Nephropathy
Extract (PTY-2r) inhibited iNOS and IL-6 by suppressing the PKC-α and NF-kB pathways in rat models [PMID:29770444]
Evidence DOsteoporosis
An ethyl acetate fraction rich in antioxidant compounds alleviated ovariectomized-induced osteoporosis in rats [PMID:33444328]
Evidence DHyperglycemia
Water extract significantly inhibits DPP-IV enzyme, resulting in glucose tolerance response in rats [PMID:29201861]
Safety & adverse effects
Methanolic extract of tubers (PTME) demonstrated hepatotoxicity in rats, with an LD(50) of 227.5 mg/100g BW; repeated doses caused increased hepatic enzymes, hepatocellular necrosis, and oxidative stress [PMID:20122980].
Pregnancy & lactation
Puerarin from P. tuberosa has been analyzed as a promising galactagogue in female rat models [PMID:40162455]. Some extracts have been tested for anti-implantation and abortifacient activity in rodents [PMID:2844661].
Evidence summary
Evidence is primarily based on in vitro studies, animal models (rats/mice/flies), and one small clinical trial (n=30) for hypertension. While promising for metabolic and cardiovascular health, safety concerns regarding hepatotoxicity at high doses in animals have been noted.
PubMed sources
1.PMID: 24980468 (2014) — Pueraria tuberosa: a review on its phytochemical and therapeutic potential. · Natural product research
2.PMID: 33708108 (2020) — Pueraria tuberosa: A Review on Traditional Uses, Pharmacology, and Phytochemistry. · Frontiers in pharmacology
3.PMID: 32021425 (2020) — Molecular Mechanisms of Anticancer Activities of Puerarin. · Cancer management and research
4.PMID: 25328218 (2014) — Effect of added herb extracts on oxidative stability of ghee (butter oil) during accelerated oxidation condition. · Journal of food science and technology
5.PMID: 40162455 (2024) — In vivo analysis of puerarin from Pueraria tuberosa as a promising galactagogue.
Government sources
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
6.PMID: 23690842 (2013) — Physical Stability and HPLC Analysis of Indian Kudzu (Pueraria tuberosa Linn.) Fortified Milk. · Evidence-based complementary and alternative medicine : eCAM
7.PMID: 20122980 (2010) — Hepatotoxicity of tubers of Indian Kudzu (Pueraria tuberosa) in rats. · Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
8.PMID: 24171260 (2012) — Effect of Pueraria tuberosa DC. (Indian Kudzu) on blood pressure, fibrinolysis and oxidative stress in patients with stage 1 hypertension. · Pakistan journal of biological sciences : PJBS
9.PMID: 2844661 (1988) — A review of Indian medicinal plants with interceptive activity. · The Indian journal of medical research
10.PMID: 33444328 (2021) — A fraction of Pueraria tuberosa extract, rich in antioxidant compounds, alleviates ovariectomized-induced osteoporosis in rats and inhibits growth of breast and ovarian cancer cells. · PloS one
11.PMID: 28218280 (2017) — Mangiferin from Pueraria tuberosa reduces inflammation via inactivation of NLRP3 inflammasome. · Scientific reports
12.PMID: 17176676 (2006) — Isoflavonoids production in callus culture of Pueraria tuberosa, the Indian kudzu. · Indian journal of experimental biology
13.PMID: 34424815 (2022) — In silico screening of Pueraria tuberosa (PTY-2) for targeting COVID-19 by countering dual targets Mpro and TMPRSS2. · Journal of biomolecular structure & dynamics
14.PMID: 33705837 (2021) — Potential of Pueraria tuberosa (Willd.) DC. to rescue cognitive decline associated with BACE1 protein of Alzheimer's disease on Drosophila model: An integrated molecular modeling and in vivo approach. · International journal of biological macromolecules
15.PMID: 39028725 (2024) — An ethnopharmacological approach to evaluate antiparasitic and health-promoting abilities of Pueraria tuberosa (Willd.) DC. in livestock. · PloS one
16.PMID: 22557128 (2004) — Determination of puerarin from pueraria tuberosa dc by HPLC. · Ancient science of life
17.PMID: 24489512 (2013) — Pueraria tuberosa DC extract improves androgenesis and sexual behavior via FSH LH cascade. · TheScientificWorldJournal
18.PMID: 36986988 (2023) — Effect of Biotic Elicitors on the Growth, Antioxidant Activity and Metabolites Accumulation in In Vitro Propagated Shoots of Pueraria tuberosa. · Plants (Basel, Switzerland)
19.PMID: 29201861 (2017) — Active phytochemicals of Pueraria tuberosa for DPP-IV inhibition: in silico and experimental approach. · Journal of diabetes and metabolic disorders
20.PMID: 29045235 (2017) — The aqueous tuber extract of Pueraria tuberosa (Willd.) D.C. caused cytotoxic effect on HT 29 cell lines with down regulation of nuclear factor-kappa B (NF-κB). · Journal of complementary & integrative medicine
21.PMID: 29770444 (2018) — Pueraria tuberosa extract inhibits iNOS and IL-6 through suppression of PKC-α and NF-kB pathway in diabetes-induced nephropathy. · The Journal of pharmacy and pharmacology
22.PMID: 28243356 (2017) — Evaluation of Anti-Inflammatory Properties of Isoorientin Isolated from Tubers of Pueraria tuberosa. · Oxidative medicine and cellular longevity